Toward the Development of Prophylactic and Therapeutic Human Papillomavirus Type-16 Lipopeptide Vaccines

Peter M. Moyle, Colleen Olive, Mei-Fong Ho, Manisha Pandey, Joanne Dyer, Andreas Suhrbier, Yoshio Fujita, Istvan Toth
  • Journal of Medicinal Chemistry, September 2007, American Chemical Society (ACS)
  • DOI: 10.1021/jm070287b

What is it about?

Human papillomavirus type-16 (HPV-16) is responsible for approximately 50 % of cervical cancers. Sequences from the E6 and E7 proteins of this virus can be used as immunotherapy to prevent and/or treat HPV-16 associated cervical cancers. This paper demonstrates the use of a branched synthetic lipopeptide vaccine development platform in combination with the HPV-16 E7(44-62) peptide antigen, an mannose as a dendritic cell targeting moiety, to produce vaccines to prevent the development of a cervical cancer model cell line (TC-1) in C57BL6 mice.

Why is it important?

Cervical cancer is an important female cancer, and is predominantly caused by prior human papillomavirus (HPV) infection. The ability to prevent HPV infection, or to treat cancers using vaccines represents an important means of reducing cervical cancer deaths.


Dr Peter Michael Moyle (Author)
University of Queensland

This paper demonstrates the potential to combine lipid adjuvants with dendritic cell targeting (mannose) and HPV cytotoxic lymphocyte epitopes to produce vaccines to prevent and/or treat HPV associated cervical cancers.

The following have contributed to this page: Dr Peter Michael Moyle